{"contentid": 488474, "importid": NaN, "name": "Lilly shares suffer on earnings miss and reduced forecast", "introduction": "Eli Lilly underwhelmed with its first-quarter 2021 financial results, sending its share price down by 2% by lunchtime on Tuesday.", "content": "<p>Eli Lilly (NYSE: LLY) underwhelmed with its first-quarter 2021 financial results, sending its share price down by 2% by lunchtime on Tuesday.</p>\n<p>The US drugmaker reported revenue of $6.8 billion, 16% higher than in the same quarter last year, but its adjusted earnings, not reported according to generally accepted accounting principles (GAAP), came in at $1.87 per share, missing the FactSet consensus estimate of $2.12 per share.</p>\n<p>Lilly also cut its earnings guidance for the full 2021 fiscal year, mainly due to weaker-than-expected sales of COVID-19 antibodies. The company now expects adjusted earnings of between $7.80 and $8, down from its previous estimate of between $7.75 and $8.40. Analysts had expected full-year earnings of $8.24 per share, according to FactSet.</p>\n<h2>'Key growth products gained volume and share'</h2>\n<p>David Ricks, Lilly's chairman and chief executive, said: &ldquo;In the first quarter of 2021, Lilly continued to advance our core business and make strategic progress to drive future growth, all while delivering hundreds of thousands of doses of our COVID-19 antibodies to patients and receiving new data for our monoclonal antibody therapies and new authorizations around the world to help fight the COVID-19 pandemic.</p>\n<p>&ldquo;Our key growth products gained volume and share, helped millions of patients with significant diseases, and represented over half of our core business. We also had a remarkable quarter in R&amp;D beyond our COVID-19 efforts, reading out key late-stage successes with mirikizumab in ulcerative colitis, donanemab in Alzheimer's, tirzepatide in diabetes, and baricitinib in alopecia areata, while early-stage research continued to deliver and advance exciting clinical-stage molecules across our core therapeutic areas.&rdquo;</p>\n<h2>Selected product sales</h2>\n<p>Trulicity (dulaglutide): $1.45 billion, up 18%</p>\n<p>COVID-19 antibodies: $810 million</p>\n<p>Humalog (insulin lispro): $617 million, down 11%</p>\n<p>Taltz (ixekizumab): $403.2 million, down 9%</p>\n<p>Humulin (insulin [human recombinant]): $321.7 million, up 2%</p>\n<p>Jardiance (empagliflozin): $312 million, up 17%</p>", "date": "2021-04-27 18:17:00", "meta_title": NaN, "meta_keywords": "Lilly, share, earnings, COVID-, reduced, suffer, forecast, shares, million, Tuesday, lunchtime, tumbling, price, sending, results, financial, first-quarter", "meta_description": "Eli Lilly (NYSE: LLY) underwhelmed with its first-quarter financial results, sending its share price tumbling by 2% by lunchtime on Tuesday.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-27 18:12:58", "updated": "2021-04-27 20:55:07", "access": NaN, "url": "https://www.thepharmaletter.com/article/lilly-shares-suffer-on-earnings-miss-and-reduced-forecast", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "eli_lilly_hq_large.jpg", "image2id": "eli_lilly_hq_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Anti-Arthritics/Rheumatics, Diabetes", "topic_tag": "Financial, Management", "geography_tag": "USA", "company_tag": "Eli Lilly", "drug_tag": "Humalog, Humulin, Taltz, Trulicity", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-27 18:17:00"}